
Opinion|Videos|February 8, 2024
CONTACT-02: Cabozantinib Plus Atezolizumab in mCRPC
Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.






































